Explanatory video: Nutrition therapy
Fresenius has a Sponsored Level 1 American Depositary Receipt (ADR) Program in the United States. The ADRs are traded under the ticker symbol "FSNUY" in the over-the-counter market tier.
ADR information
Structure | Sponsored Level 1 ADR |
Ratio (ADR:ORD) | 4:1 |
Trading Location | OTC |
Ticker Symbol | FSNUY |
CUSIP | 35804M105 |
ISIN | US35804M1053 |
Trading in ADR
ADRs represent ordinary or common shares of a non-U.S. company. Four Fresenius ADRs are the equivalent of one Fresenius ordinary share. They are priced in U.S. dollars and traded in the U.S. over-the-counter (OTC) market. Deutsche Bank is acting as the depositary bank for this ADR program.
Contact details for ADR brokers & institutional investors:
U.S. Tel: +1 212 250 9100
UK Tel: +44 207 547 6500
e-mail: adr@db.com
Contact details for registered ADR Holders:
Deutsche Bank Shareholder Services
American Stock Transfer & Trust Company
Peck Slip Station
P.O. Box 2050
New York, NY 10272-2050
e-mail: DB@amstock.com
Toll-free number: +1 800 937 5449
Direct Dial: +1 718 921 8124
Fresenius’ ADR program is administered by Deutsche Bank Trust Company Americas (Deutsche Bank). As the depositary bank, Deutsche Bank performs the following roles for ADR holders as further detailed in the Deposit Agreement:
- Records and maintains the register of ADR holders,
- Is the stock transfer agent,
- Distributes dividends in U.S. dollars,
- Facilitates the voting process and the exercise of the voting rights of ADR holders at any Company
- General Meeting if permitted by the Company and the Depositary Agreement,
- Issues and cancels Fresenius American Depositary Receipts (ADRs),
- Can distribute Company circulars and General Meetings (including Annual General Meeting) documentation, if applicable.
For those holders who are not registered because their ADRs are held through a ‘Street name’ (nominee account), your nominee will from time to time receive Company documents from Deutsche Bank to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at General Meetings (if applicable).
Contact
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com
Related Links
Historical ADR prices and interactive chartsInternational financial analysts cover Fresenius SE & Co. KGaA and publish reports and updates on the development of its business and its shares. Once a quarter, VARA Research creates an up-to-date consensus from these various forecasts. An interactive and downloadable set of the consensus data for Fresenius SE & Co. KGaA can be found on Vara Research.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolDownload
Event
November 06, 2024 - 01:30 pm | Bad Homburg, Germany
Webcast replay
Webcast replay Aide Memoire Q3/24 Investor News Presentation Transcript Import (ICS)Fresenius SE & Co. KGaA's subscribed capital amounts to €563,237,277 and consists of 563,237,277 ordinary shares (last change as of 09.06.2022). The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Capitalization
| Date | Capital-related measures | Subscribed Capital / Total number of ordinary Shares |
|---|---|---|
09.06.2022 | Issuance of new shares (scrip dividend) | €563,237,277 / 563,237,277 |
30.11.2021 | Issuance of new shares from stock option plan | €558,502,143 / 558,502,143 |
31.10.2021 | Issuance of new shares from stock option plan | €558,457,143 / 558,457,143 |
30.09.2021 | Issuance of new shares from stock option plan | €558,454,143 / 558,454,143 |
31.08.2021 | Issuance of new shares from stock option plan | €558,453,018 / 558,453,018 |
31.07.2021 | Issuance of new shares from stock option plan | €558,437,193 / 558,437,193 |
30.06.2021 | Issuance of new shares from stock option plan | €558,040,523 / 558,040,523 |
31.05.2021 | Issuance of new shares from stock option plan | €557,716,248 / 557,716,248 |
30.04.2021 | Issuance of new shares from stock option plan | €557,556,509 / 557,556,509 |
31.03.2021 | Issuance of new shares from stock option plan | €557,541,659 / 557,541,659 |
| Date | Capital-related measures | ||
|---|---|---|---|
Subcribed Capital | Nominal Value | Total number of preference shares | Total number of ordinary shares |
2021 | Issuance of new shares from stock option plan | ||
€ 558,502,143 | 558,502,143 | ||
2020 | Issuance of new shares from stock option plan | ||
€ 557,540,909 | 557,540,909 | ||
2019 | Issuance of new shares from stock option plan | ||
€ 557,379,979 | 557,379,979 | ||
2018 | Issuance of new shares from stock option plan | ||
€ 556,225,154 | 556,225,154 | ||
2017 | Issuance of new shares from stock option plan | ||
€ 554,710,473 | 554,710,473 | ||
31.01.2017 | Capital increase from approved capital | ||
€ 553,316,547 | 553,316,547 | ||
2016 | Issuance of new shares from stock option plan | ||
€ 547,208,371 | 547,208,371 | ||
2015 | Issuance of new shares from stock option plan | ||
€ 545,727,950 | 545,727,950 | ||
2014 | Issuance of new shares from stock option plan | ||
€ 541,532,600 | 541,532,600 | ||
01.08.2014 | Stock split with Capital increase from company funds | ||
€ 540,511,632 | 540,511,632 | ||
31.07.2014 | Issuance of new shares from stock option plan | ||
€ 180,170,544 | 180,170,544 | ||
31.07.2014 | Issuance of new shares from stock option plan | ||
€ 180,170,544 | 180,170,544 | ||
2013 | Issuance of new shares from stock option plan | ||
€ 179,694,829 | 179,694,829 | ||
2012 | Issuance of new shares from stock option plan | ||
€ 178,188,260 | 178,188,260 | ||
15.05.2012 | Capital increase from approved capital | ||
€ 177,166,002 | 177,166,002 | ||
30.04.2012 | Issuance of new shares from stock option plan | ||
€ 163,366,002 | 163,366,002 | ||
2011 | Issuance of new shares from stock option plan | ||
€ 163,237,336 | 163,237,336 | ||
28.01.2011 | Unification of share classes | ||
€ 162,450,090 | 162,450,090 | ||
2010 | Issuance of new shares from stock option plan (P&O) | ||
€ 162,450,090 | 81,225,045 | 81,225,045 | |
2009 | Issuance of new shares from stock option plan (P&O) | ||
€ 161,315,376 | 80,657,688 | 80,657,688 | |
2008 | Issuance of new shares from stock option plan (P&O) | ||
€ 161,143,734 | 80,571,867 | 80,571,867 | |
| Capital increase from approval capital | ||
€ 160,863,550 | 80,426,775 | 80,426,775 | |
| Issuance of new shares from stock option plan (P&O) | ||
€ 155,357,436 | 77,678,718 | 77,678,718 | |
2007 | Issuance of new shares from stock option plan (P&O) | ||
€ 155,164,770 | 77,582,385 | 77,582,385 | |
| Share split with capital increase from the Company's funds4 | |||
€ 154,353,876 | 77,176,938 | 77,176,938 | |
2006 | Issuance of new shares from stock option plan (P&O) | ||
€ 131,715,308 | 25,725,646 | 25,725,646 | |
17.11.2006 | Capital increase through contribution in kind (P&O) | ||
€ 131.524.890 | 176,540 | 176,540 | |
2005 | Capital increase from approved capital 9:2 (P&O) | ||
€ 129,849,037 | 25,361,140 | 25,361,140 | |
2005 | Issuance of new shares from stock option plan (P&O) | ||
€ 105,785,037 | 20,661,140 | 20,661,140 | |
2004 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,885,857 | 20,485,519 | 20,485,519 | |
2002 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,882,391 | 20,484,842 | 20,484,842 | |
2001 | Issuance of new shares from stock option plan (P&O) | ||
€ 104,882,043 | 20,484,774 | 20,484,774 | |
| Capital increase through contribution in kind (P&O) | |||
€ 104,800,266 | 20,468,802 | 20,468,802 | |
| Capital increase from corporate funds by new share issue in the ratio 1:1 (P&O) | |||
€ 102,477,865 | 20,015,208 | 20,015,208 | |
| Issuance of new shares from stock option plan (P&O) | |||
€ 51,238,932 | 10,007,604 | 10,007,604 | |
2000 | Issuance of new shares from stock option plan (P&O) | ||
€ 51,238,523 | 10,007,524 | 10,007,524 | |
1999 | Conversion of subscribed capital into € and introduction of non-par shares3 | ||
€ 51,200,000 | 10,000,000 | 10,000,000 | |
1997 | Capital increase (P) | ||
DM 100,000,000 | DM 5 | 10,000,000 | 10,000,000 |
1995 | Change of nominal value from DM 50 to DM 5 | ||
DM 90,000,000 | DM 5 | 8,000,000 | 10,000,000 |
1994 | Capital increase (P) | ||
DM 90,000,000 | DM 50 | 800,000 | 1,000,000 |
1992 | Capital increase / listing (O)2 | ||
DM 80,000,000 | DM 50 | 600,000 | 1,000,000 |
1989 | Capital increase (P) | ||
DM 60,000,000 | DM 50 | 600,000 | 600,000 |
1986 | Listing at Frankfurt Stock Exchange (P)1 | ||
DM 45,000,000 | DM 50 | 300,000 | 600,000 |
-
1 (P) = Preference Shares
2 (O) = Ordinary Shares
3 Par value per share € 2.56
4 Par value per share € 1.00
105,288,804 shares of total share capital are not listed.
Notification pursuant to Art. 2 (3) Sentence 2 DELEGATED REGULATION (EU) No 2016/1052
Employee participation in our corporate success has a long tradition at Fresenius. Last year, the employee share program "Fresenius SHARE" was launched. Attached please find an overview of transactions in connection with our employee share program.
Related Links
Interactive ToolEvent
November 06, 2024 - 01:30 pm | Bad Homburg, Germany
Webcast replay
Webcast replay Aide Memoire Q3/24 Investor News Presentation Transcript Import (ICS)The Group’s maturity profile is characterized by a broad spread of maturities with a large proportion of mid- to long-term financing.
Well-balanced maturity profile of the Fresenius Group1
1 As of September 30, 2024, and based on utilization of major financing instruments, excl. Commercial Paper and other cash management lines
2 Calculations based on total financial debt, excluding Lease & Purchase Money Obligations
Download debt maturity profile and additional information
Related Links
Financing MixHere you will find the key figures for the Fresenius Group. Additional key financial figures are available at our interactive analysis tool, which can be used to process or analyze the figures in graphical form.
Key Credit Figures Fresenius Group (IFRS)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
Net debt/EBITDA1,2,3 | 3.76 | 3.80 | 3.64 |
| |||
Debt (€m)1,2 | 15,830 | 14,708 | - |
Net debt (€m)1,2 | 13,268 | 13,316 | 12,650 |
| |||
Cash Conversion Rate1 | 1.0 | 0.9 | 0.9 |
EBITDA/Financial result1,2,3 | 8.2 | 13.8 | 15.0 |
-
1 The previous year’s figures were adjusted due to the application of IFRS 5 to the deconsolidated activities of Fresenius Medical Care
2 For pro forma acquisitions/divestitures
3 Before special items
The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP).
Commercial Paper Program
| Issuer | Fresenius SE & Co. KGaA, Fresenius Finance Ireland plc. |
|---|---|
Program amount | € 1,500,000,000 |
Arranger | Commerzbank |
Dealer | Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, ING Bank N.V. |
Issuing and paying agent | Commerzbank |
Term | up to 1 year less 1 day |
With its broad mix of financing instruments, Fresenius is well positioned to meet its financing needs. The spectrum of our financing instruments takes market capacity, investor diversification, utilization flexibility, credit covenants, and the current maturity profile into consideration.
Financing instruments
Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.
Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.